newsfilter
← Earnings
Earnings Releases·

Exagen Inc. — Third Quarter 2026 Earnings Summary

Exagen Inc. reported third-quarter 2026 revenue of $18.4 million, representing a 7% increase compared to the same period in 2025. The company achieved a trailing twelve-month average selling price of $451 per test for its AVISE CTD offering, marking the 14th consecutive quarter of growth. For the nine months ended September 30, 2026, total revenue reached $55.7 million while the net loss decreased to $13.5 million from $15.3 million in the prior year period. Exagen reiterated its full-year 2026 revenue guidance of $72 million to $75 million and ended the quarter with approximately $28.1 million in cash and cash equivalents.

Company
EXAGEN INC
Sector
Healthcare
Industry
Diagnostics & Research